Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 'Smart Bomb' drug enters human testing for multiple advanced cancers

NCT ID NCT06400472

Recruiting now Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new targeted cancer drug called LY4170156. It aims to find a safe dose and see if it can help control advanced cancers, including ovarian, lung, breast, and pancreatic cancers. The study will also test the drug in combination with other common cancer treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Institute Hospital of JFCR

    RECRUITING

    Tokyo, 135-8550, Japan

  • Cancer Research SA

    RECRUITING

    Adelaide, 5000, Australia

  • Centre Leon Berard

    RECRUITING

    Lyon, 69373, France

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • HonorHealth

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Hospital Clinico Universitario de Valencia

    RECRUITING

    Valencia, 46010, Spain

  • Hospital Universitario 12 de Octubre

    RECRUITING

    Madrid, 28041, Spain

  • Hospital Universitario Vall d'Hebron

    RECRUITING

    Barcelona, 08035, Spain

  • Icon Cancer Centre South Brisbane

    RECRUITING

    QLD, 4101, Australia

  • Institut de Cancerologie de l'Ouest - site St-Herblain

    RECRUITING

    Saint-Herblain, 44805, France

  • Istituto Clinico Humanitas

    RECRUITING

    Rozzano, 20089, Italy

  • Istituto Europeo di Oncologia

    RECRUITING

    Milan, 20141, Italy

  • NYU Langone Health - Long Island

    RECRUITING

    Mineola, New York, 11501, United States

  • National Cancer Center

    RECRUITING

    Goyang-si Gyeonggi-do, 10408, South Korea

  • National Cancer Center Hospital

    RECRUITING

    Tokyo, 104-0045, Japan

  • New York University (NYU) Clinical Cancer Center

    RECRUITING

    New York, New York, 10016, United States

  • Oncopole Claudius Regaud

    RECRUITING

    Toulouse, 31059, France

  • START Mountain Region

    RECRUITING

    West Valley City, Utah, 84119, United States

  • Shizuoka Cancer Center

    RECRUITING

    Shizuoka, 411-8777, Japan

  • South Texas Accelerated Research Therapeutics (START) Midwest

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • The Ohio State University (OSU) Wexner Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

  • The University of Texas - MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030-4000, United States

  • University of California, San Diego (UCSD) - Moores Cancer Center

    RECRUITING

    La Jolla, California, 92037, United States

Conditions

Explore the condition pages connected to this study.

CARCINOMA, NON-SMALL-CELL LUNG COLORECTAL NEOPLASMS ENDOMETRIAL NEOPLASMS OVARIAN NEOPLASMS PANCREATIC NEOPLASM TRIPLE NEGATIVE BREAST NEOPLASMS UTERINE CERVICAL NEOPLASMS